BioTherapeutics, Inc., incorporated in Virginia in 2008, is an early stage biotechnology company focused on
Developing Safer Therapies from Nature’s Innovations
The company has identified a novel mechanism of action (MOA)/pathway - LANCL2 - for glucose lowering and inflammation and has developed a number of lead candidates in preclinical testing in its pipeline.
